Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • AbbVie, Merck, Pfizer, UCB sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. UCB Group (Euronext:UCB), Brussels, Belgium Business: Autoimmune The U.K.s NICE issued final …

    Published on 2/8/2016
  • Actelion, Nippon Shinyaku sales and marketing update

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Nippon Shinyaku Co. Ltd. (Tokyo:4516), Kyoto, Japan Business: Cardiovascular In January, Actelion launched Uptravi selexipag in the U.S. to treat pulmonary arterial …

    Published on 2/8/2016
  • Novartis, Aetna sales and marketing update

    Novartis (NYSE:NVS; SIX:NOVN), Basel, Switzerland Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Cardiovascular Novartis said it agreed to outcomes-based pricing for heart failure drug Entresto sacubitril/valsartan …

    Published on 2/8/2016
  • Selah Genomics, Greenville Health System sales and marketing update

    Selah Genomics Inc., Greenville, S.C. Greenville Health System, Greenville, S.C. Business: Diagnostic Selah Genomics launched the mySUDDinCode test in the U.S. to determine the risk of sudden cardiac death. Selah said …

    Published on 2/8/2016
  • Taisho Pharmaceutical Holdings, Teijin sales and marketing update

    Taisho Pharmaceutical Holdings Co. Ltd. (Tokyo:4581), Tokyo, Japan Teijin Pharma Ltd., Tokyo, Japan Business: Neurology Teijin launched Loqoa Tape in Japan to treat pain and inflammation in patients with osteoarthritis…

    Published on 2/8/2016
  • Valeant Pharmaceuticals, Express Scripts sales and marketing update

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Business: Endocrine/Metabolic Express Scripts said it excluded Valeants Glumetza …

    Published on 2/8/2016
  • AbbVie, Bristol-Myers, Gilead sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Late last year, the U.K.s NICE issued final …

    Published on 2/1/2016
  • AbbVie, Bristol-Myers, Merck, Pfizer, Roche, UCB sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, …

    Published on 2/1/2016
  • AbbVie, Bristol-Myers, Pfizer, Roche sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Pfizer Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Autoimmune Late last year, the…

    Published on 2/1/2016
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Pulmonary, Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment reexamining Bretaris/Eklira Genuair …

    Published on 2/1/2016
  • Baxalta sales and marketing update

    Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Business: Hematology Late last year, Baxalta launched Adynovate in the U.S. to treat hemophilia A. The wholesale acquisition cost (WAC) for Adynovate is $1.98 per 1 IU dose. The…

    Published on 2/1/2016
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer The U.K.s NICE issued final guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), …

    Published on 2/1/2016
  • Bio Products Laboratory sales and marketing update

    Bio Products Laboratory Ltd., Elstree, U.K. Business: Hematology Late last year, Bio Products Laboratory launched Coagadex in the U.S. for on-demand treatment and control of bleeding episodes in patients ages 12 and …

    Published on 2/1/2016
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary The U.K.s NICE issued final guidance recommending Ofev nintedanib from Boehringer to treat idiopathic pulmonary fibrosis (IPF) -- its approved indication…

    Published on 2/1/2016
  • Bristol-Myers, Ono Pharmaceutical sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) issued a dossier …

    Published on 2/1/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune Late last year, the U.K.s NICE issued final guidance recommending against the use of Otezla apremilast from Celgene to treat psoriatic arthritis in patients…

    Published on 2/1/2016
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The U.K.s NICE issued final guidance recommending against the use of Cyramza ramucirumab from Eli Lilly to treat advanced gastric cancer or gastro-…

    Published on 2/1/2016
  • GlaxoSmithKline sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Inflammation Late last year, GlaxoSmithKline launched Nucala mepolizumab in the U.S. to treat severe eosinophilic asthma in patients at least 12 years old.…

    Published on 2/1/2016
  • Lundbeck, Takeda sales and marketing update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology Late last year, the U.K.s NICE issued final guidance recommending Brintellix vortioxetine from…

    Published on 2/1/2016
  • Medivation, Astellas sales and marketing update

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer The U.K.s NICE issued final guidance recommending Xtandi enzalutamide from Astellas to treat hormone-…

    Published on 2/1/2016
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer The U.K.s NICE issued final guidance recommending Farydak panobinostat from Novartis to treat multiple myeloma (MM) in patients who have received two…

    Published on 2/1/2016
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk launched Tresiba insulin degludec in the U.S. to improve glycemic control in adult Type I and II diabetics. The …

    Published on 2/1/2016
  • Thermo Fisher, Samsung Electronics sales and marketing update

    Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Samsung Electronics Co. Ltd. (LSE:SMSN; KSE:005930), Suwon, South Korea Business: Diagnostic Thermo Fisher launched the Samsung IB BRAHMS PCT assay in Europe to …

    Published on 2/1/2016
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Endocrine/Metabolic The French National Authority for Health (HAS) recommended that Repatha evolocumab from Amgen be covered by the public health insurance only …

    Published on 1/25/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that Imnovid pomalidomide from Celgene has no hint of added …

    Published on 1/25/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993